IMCR7:00 AMImmunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanomaEnrollment • Phase 3Enrollment milestone Mon, Sep 14, 2026, 7:00 AM EDTGimmunocore.com
IMCR7:00 AMImmunocore reports second quarter financial results and provides a business updateEnrollment • Phase 3presentation Thu, Aug 6, 2026, 7:00 AM EDTGimmunocore.com
IMCR7:00 AMImmunocore to report second quarter 2026 financial results and host call on August 6, 2026immunocore.com